Author:
Huang Ru-Lin,Sun Yangbai,Ho Chia-Kang,Liu Kai,Tang Qi-Qun,Xie Yun,Li Qingfeng
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference46 articles.
1. US Food and Drug Administration: InFUSE Bone Graft/LTCAGE Lumbar Tapered Fusion Device. Summary of safety and effective data premarket approval application P000058. Available at
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm083423.htm
2. Dimar, J. R. 2nd et al. Clinical and radiographic analysis of an optimized rhBMP-2 formulation as an autograft replacement in posterolateral lumbar spine arthrodesis. J. Bone Jt. Surg. Am. 91, 1377–1386 (2009).
3. Hoffmann, M. F., Jones, C. B. & Sietsema, D. L. Recombinant Human bone morphogenetic protein-2 in posterolateral spinal fusion: What’s the right dose? Asian Spine J. 10, 457–464 (2016).
4. Hong, J. Y. et al. A high concentration of recombinant human bone morphogenetic protein-2 induces low-efficacy bone regeneration in sinus augmentation: a histomorphometric analysis in rabbits. Clin. Oral Implants Res. 27, e199–e205 (2016).
5. Zara, J. N. et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo. Tissue Eng. Part A. 17, 1389–1399 (2011).
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献